Veraxa Biotech CEO buys 5,000 shares at $1.53

Veraxa Biotech AG (VRXA) reported that Chief Executive Officer and director Christoph Rudiger Antz purchased 5,000 Ordinary Shares on 2026-08-27 in a non-derivative, open-market or private transaction at a price of $1.53 per share.

Rhea-AI Filing Summary

Veraxa Biotech AG (VRXA) reported that Chief Executive Officer and director Christoph Rudiger Antz purchased 5,000 Ordinary Shares on 2026-08-27 in a non-derivative, open-market or private transaction at a price of $1.53 per share. Following this transaction, he directly owns 5,000 Ordinary Shares.

Insider Trade Summary

Net Buyer: 5,000 shares

Net Buy 1 txn

Insider Antz Christoph Rudiger

Role Chief Executive Officer

Bought 5,000 shs ($8K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares	5,000	$1.53	$8K

Holdings After Transaction: Ordinary Shares — 5,000 shares (Direct)

Key Figures

Shares purchased: 5,000 Ordinary Shares Purchase price per share: $1.53 per share Shares owned after transaction: 5,000 Ordinary Shares +1 more

4 metrics

Shares purchased 5,000 Ordinary Shares Non-derivative purchase on 2026-08-27

Purchase price per share $1.53 per share Ordinary Shares transaction on 2026-08-27

Shares owned after transaction 5,000 Ordinary Shares Direct ownership reported following the purchase

Net buy shares 5,000 shares transactionSummary netBuySellShares for this Form 4

Key Terms

non-derivative, direct ownership, transaction code P

3 terms

non-derivative financial

"The transaction is classified as non-derivative"

direct ownership financial

"The ownership_type for the shares is direct"

transaction code P financial

"transaction_code "P" indicates a purchase"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did VRXA report in this Form 4?

VRXA reported that Chief Executive Officer and director Christoph Rudiger Antz purchased 5,000 Ordinary Shares on 2026-08-27 in a non-derivative transaction at $1.53 per share, resulting in direct ownership of 5,000 Ordinary Shares.

Who is the insider involved in the latest VRXA Form 4 filing?

The insider is Christoph Rudiger Antz, who serves as both Chief Executive Officer and director of Veraxa Biotech AG, according to the Form 4 data.

How many VRXA shares did the CEO buy and at what price?

Christoph Rudiger Antz purchased 5,000 Ordinary Shares of VRXA at a price of $1.53 per share on 2026-08-27 in a non-derivative, open-market or private transaction.

What is the CEO’s direct ownership in VRXA after this transaction?

After the reported transaction, Chief Executive Officer Christoph Rudiger Antz directly owns 5,000 Ordinary Shares of VRXA, as stated in the Form 4 total_shares_following_transaction field.

Was the VRXA CEO’s share purchase under a Rule 10b5-1 trading plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox (aff_10b5_one) is false, meaning the transaction was not affirmatively reported as being made pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 04:10 PM EDT Accepted by SEC EDGAR 08/31/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Antz Christoph Rudiger

(Last) (First) (Middle)

TALACKER 35

(Street)

ZURICH V8 8001

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Veraxa Biotech AG - Post de-SPAC [ VRXA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/27/2026		P		5,000	A	$1.53	5,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Christoph Antz, Chief Executive Officer	08/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)